MedicalCV Inc. has received approval from the US Food and Drug Administration for the company’s Omnicarbon(TM) cardiac valve. With the PMA, the Omnicarbon aortic and mitral valves are now available in the USA as a replacement for diseased heart valves. The Omnicarbon valve has been in use outside the United States since 1984 and to date, approximately 30,000 Omnicarbon valves have been implanted in patients in more than 30 countries. Stora Enso’s board approves new PM plans for Langerbrugge mill in Belgium.
